1. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol 2017;76:432-40.e17.
2. Reich K, Leonardi C, Ohtsuki M, Gooderham M, Pangallo B, Xu WI, et al. Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions in Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab Compared with Placebo or Etanercept from Three Phase 3 Trials. In Vienna, Austria; 2016.
3. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials;Griffiths;Lancet,2015
4. Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis;Henderson;J Drugs Dermatol,2017
5. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor alpha receptor: Fc fusion protein;Zeltser;Arch Dermatol,2001